- Home
- CTO vs MLYS Comparison
CTO vs MLYS Comparison
Compare CTO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- MLYS
- Stock Information
- Founded
- CTO 1902
- MLYS 2019
- Country
- CTO United States
- MLYS United States
- Employees
- CTO N/A
- MLYS N/A
- Industry
- CTO Real Estate Investment Trusts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- MLYS Health Care
- Exchange
- CTO Nasdaq
- MLYS Nasdaq
- Market Cap
- CTO 580.9M
- MLYS 526.1M
- IPO Year
- CTO N/A
- MLYS 2023
- Fundamental
- Price
- CTO $19.78
- MLYS $10.21
- Analyst Decision
- CTO Strong Buy
- MLYS Strong Buy
- Analyst Count
- CTO 4
- MLYS 2
- Target Price
- CTO $21.50
- MLYS $30.00
- AVG Volume (30 Days)
- CTO 220.6K
- MLYS 263.5K
- Earning Date
- CTO 02-20-2025
- MLYS 03-20-2025
- Dividend Yield
- CTO 7.68%
- MLYS N/A
- EPS Growth
- CTO N/A
- MLYS N/A
- EPS
- CTO 0.61
- MLYS N/A
- Revenue
- CTO $118,662,000.00
- MLYS N/A
- Revenue This Year
- CTO N/A
- MLYS N/A
- Revenue Next Year
- CTO $13.12
- MLYS N/A
- P/E Ratio
- CTO $32.77
- MLYS N/A
- Revenue Growth
- CTO 16.61
- MLYS N/A
- 52 Week Low
- CTO $16.16
- MLYS $8.58
- 52 Week High
- CTO $21.15
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- CTO 53.69
- MLYS 44.53
- Support Level
- CTO $19.26
- MLYS $9.57
- Resistance Level
- CTO $19.77
- MLYS $10.79
- Average True Range (ATR)
- CTO 0.35
- MLYS 0.64
- MACD
- CTO 0.04
- MLYS 0.11
- Stochastic Oscillator
- CTO 73.26
- MLYS 63.98
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a Florida-based real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.